Aiming for a Society Where Correct Medical Information Reaches Every Corner
Interscience Co., Ltd. announces its April Dream to promote the widespread dissemination of accurate medical information through its disease information website "Medicil."
📋 Article Processing Timeline
- 📰 Published: April 1, 2026 at 09:00
- 🔍 Collected: April 1, 2026 at 01:00
- 🤖 AI Analyzed: April 6, 2026 at 16:02 (135h 1m after Collected)
Our company supports April Dream, which aims to make April 1st a day to express dreams. This press release is the dream of "Medicil," a disease information website operated by Interscience Co., Ltd., which allows users to "see + know."
## Background of the Dream
Modern medicine continues to make steady progress, and the means and information for accessing appropriate medical care are increasingly widespread. However, in the field of intractable diseases (designated intractable diseases) and rare diseases, various challenges still remain.
For example, are you familiar with the term "diagnostic lag"? This term symbolizes the long period it takes for individuals with intractable or rare diseases to receive a diagnosis after the onset of initial symptoms. On average, it takes 3.4 years*1), and 35% of all patients (approximately 1 in 3)*2) require more than 5 years for diagnosis.
Diagnostic lag is a problem caused by a combination of several factors, and "lack of information dissemination" is one of them. We have witnessed numerous cases where "things that could have been addressed early if known were overlooked."
This situation of "information not reaching" is a serious issue surrounding patients with intractable and rare diseases, not limited to its impact on diagnostic lag. Data shows that 53% of patients with rare diseases (approximately 1 in 2)*3) have experienced difficulties in collecting information about their illness. Even after diagnosis, they face problems such as "difficulty finding reliable information online," "information being full of technical terms and hard to read," "anxiety due to not fully understanding their own illness," and "difficulty getting people close to them to understand their situation."
*1) Joint survey by JMDC Co., Ltd. (https://www.jmdc.co.jp/) and Alexion Pharma
*2) "Survey conducted by Charles River Associates (CRA) targeting patients with rare and intractable diseases in Japan (conducted from December 2024 to February 2025)"
*3) JPMA "Survey on Difficulties Faced by Patients with Rare Diseases" conducted from October to November 2022
## Believing that "knowing" is the first step to appropriate medical care
We, Interscience Co., Ltd., usually produce specialized content for doctors, healthcare professionals, and diagnosed patients. Amidst the challenge of "patients delaying the start of appropriate treatment," and with the desire to help them connect to appropriate medical care as quickly as possible, we recruited volunteers within the company last year and launched "Medicil," a disease information website focusing mainly on rare and intractable diseases for which information for the general public is insufficient.
As a communication agency, we cannot directly conduct patient treatment or research on treatment methods. However, we believe that by disseminating appropriate medical information in an easy-to-understand format for everyone, we can support more people to reach an early diagnosis and start treatment. Our dream is "to create a society where correct medical information reaches every corner."
### Medicil's Initiatives
Medical information often contains many technical terms and a vast amount of data, making it difficult for many to understand. Medicil strives to provide specialized medical information in easy-to-understand video content that anyone, from adults to children, can comprehend.
While the internet is flooded with unverified information, it is crucial for medical information, in particular, to be accurate and evidence-based. Medicil provides only information supervised by doctors. Although the number of videos currently available is small, we are working daily to expand our content further and contribute to the realization of "a world where no one suffers from rare or intractable diseases."
Click here for "Medicil," the "See + Know" disease information website:
https://www.medicil.jp/
[About Interscience Co., Ltd.]
Interscience Co., Ltd. is a communication agency founded in 1988, specializing in ethical pharmaceuticals.
It boasts the largest number of medical writers in Japan and is dedicated to providing accurate information on medicine and healthcare as its corporate philosophy.
Contact us here for inquiries about the disease information website Medicil:
https://www.medicil.jp/inquiry/
## Background of the Dream
Modern medicine continues to make steady progress, and the means and information for accessing appropriate medical care are increasingly widespread. However, in the field of intractable diseases (designated intractable diseases) and rare diseases, various challenges still remain.
For example, are you familiar with the term "diagnostic lag"? This term symbolizes the long period it takes for individuals with intractable or rare diseases to receive a diagnosis after the onset of initial symptoms. On average, it takes 3.4 years*1), and 35% of all patients (approximately 1 in 3)*2) require more than 5 years for diagnosis.
Diagnostic lag is a problem caused by a combination of several factors, and "lack of information dissemination" is one of them. We have witnessed numerous cases where "things that could have been addressed early if known were overlooked."
This situation of "information not reaching" is a serious issue surrounding patients with intractable and rare diseases, not limited to its impact on diagnostic lag. Data shows that 53% of patients with rare diseases (approximately 1 in 2)*3) have experienced difficulties in collecting information about their illness. Even after diagnosis, they face problems such as "difficulty finding reliable information online," "information being full of technical terms and hard to read," "anxiety due to not fully understanding their own illness," and "difficulty getting people close to them to understand their situation."
*1) Joint survey by JMDC Co., Ltd. (https://www.jmdc.co.jp/) and Alexion Pharma
*2) "Survey conducted by Charles River Associates (CRA) targeting patients with rare and intractable diseases in Japan (conducted from December 2024 to February 2025)"
*3) JPMA "Survey on Difficulties Faced by Patients with Rare Diseases" conducted from October to November 2022
## Believing that "knowing" is the first step to appropriate medical care
We, Interscience Co., Ltd., usually produce specialized content for doctors, healthcare professionals, and diagnosed patients. Amidst the challenge of "patients delaying the start of appropriate treatment," and with the desire to help them connect to appropriate medical care as quickly as possible, we recruited volunteers within the company last year and launched "Medicil," a disease information website focusing mainly on rare and intractable diseases for which information for the general public is insufficient.
As a communication agency, we cannot directly conduct patient treatment or research on treatment methods. However, we believe that by disseminating appropriate medical information in an easy-to-understand format for everyone, we can support more people to reach an early diagnosis and start treatment. Our dream is "to create a society where correct medical information reaches every corner."
### Medicil's Initiatives
Medical information often contains many technical terms and a vast amount of data, making it difficult for many to understand. Medicil strives to provide specialized medical information in easy-to-understand video content that anyone, from adults to children, can comprehend.
While the internet is flooded with unverified information, it is crucial for medical information, in particular, to be accurate and evidence-based. Medicil provides only information supervised by doctors. Although the number of videos currently available is small, we are working daily to expand our content further and contribute to the realization of "a world where no one suffers from rare or intractable diseases."
Click here for "Medicil," the "See + Know" disease information website:
https://www.medicil.jp/
[About Interscience Co., Ltd.]
Interscience Co., Ltd. is a communication agency founded in 1988, specializing in ethical pharmaceuticals.
It boasts the largest number of medical writers in Japan and is dedicated to providing accurate information on medicine and healthcare as its corporate philosophy.
Contact us here for inquiries about the disease information website Medicil:
https://www.medicil.jp/inquiry/
FAQ
What kind of website is Medicil?
Medicil is a disease information website specializing in intractable and rare diseases, providing accurate, doctor-supervised medical information in an easy-to-understand video format.
What is diagnostic lag?
Diagnostic lag refers to the long period from the onset of initial symptoms to diagnosis for patients with intractable or rare diseases, averaging 3.4 years.
What is Interscience Co., Ltd.'s role?
As a communication agency specializing in ethical pharmaceuticals, it aims to contribute to society by producing and disseminating medical information.